Centene Corp CNC
We take great care to ensure that the data presented and summarized in this overview for CENTENE CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNC
View all-
Vanguard Group Inc Valley Forge, PA60.9MShares$4.76 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY42.3MShares$3.3 Billion0.08% of portfolio
-
Capital World Investors Los Angeles, CA26.9MShares$2.1 Billion0.36% of portfolio
-
State Street Corp Boston, MA23.4MShares$1.83 Billion0.08% of portfolio
-
Wellington Management Group LLP Boston, MA19.8MShares$1.54 Billion0.28% of portfolio
-
Harris Associates L P Chicago, IL17MShares$1.33 Billion2.21% of portfolio
-
Politan Capital Management LP New York, NY12.1MShares$947 Million49.54% of portfolio
-
Swedbank Ab Stockholm, V711.6MShares$909 Million1.54% of portfolio
-
Geode Capital Management, LLC Boston, MA10.7MShares$834 Million0.08% of portfolio
-
Jpmorgan Chase & CO New York, NY9.59MShares$748 Million0.07% of portfolio
Latest Institutional Activity in CNC
Top Purchases
Top Sells
About CNC
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Insider Transactions at CNC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Frederick H Eppinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,861
+1.37%
|
-
|
May 14
2024
|
Monte E Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+28.67%
|
-
|
May 14
2024
|
Lori Jean Robinson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+16.87%
|
-
|
May 14
2024
|
Theodore R. Samuels Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+18.43%
|
-
|
May 14
2024
|
Jessica L. Blume Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+10.53%
|
-
|
May 14
2024
|
Kenneth A Burdick Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+0.8%
|
-
|
May 14
2024
|
Christopher J Coughlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+10.26%
|
-
|
May 14
2024
|
H James Dallas Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+6.75%
|
-
|
May 14
2024
|
Wayne S De Veydt Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+17.94%
|
-
|
May 13
2024
|
Kenneth J Fasola President |
SELL
Open market or private sale
|
Direct |
8,000
-2.59%
|
$616,000
$77.62 P/Share
|
May 07
2024
|
Andrew Lynn Asher Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,559
-1.38%
|
$491,925
$75.14 P/Share
|
Apr 26
2024
|
Andrew Lynn Asher Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,638
-0.96%
|
$347,850
$75.68 P/Share
|
Apr 01
2024
|
Katie Casso Corporate Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
922
-1.49%
|
$71,916
$78.48 P/Share
|
Mar 31
2024
|
Kenneth A Burdick Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+0.11%
|
-
|
Mar 31
2024
|
Christopher J Coughlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+1.69%
|
-
|
Mar 31
2024
|
Wayne S De Veydt Director |
BUY
Grant, award, or other acquisition
|
Direct |
420
+3.87%
|
-
|
Mar 31
2024
|
Frederick H Eppinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
323
+0.09%
|
-
|
Mar 31
2024
|
Theodore R. Samuels Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
323
+3.13%
|
-
|
Mar 15
2024
|
Katie Casso Corporate Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
11,834
+16.04%
|
-
|
Mar 15
2024
|
Katie Casso Corporate Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,539
-2.98%
|
$116,964
$76.05 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 505K shares |
---|---|
Exercise of conversion of derivative security | 10K shares |
Payment of exercise price or tax liability | 165K shares |
---|---|
Open market or private sale | 30K shares |